Legend Biotech stock reports Q2 profit as target stays at USD 65.00

Published on 09/28/2026 at 23:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Legend Biotech stock closed at USD 19.11 on September 25, 2026, while H.C. Wainwright kept a USD 65.00 target. Q2 revenue rose 51.9 percent year over year.

LEGN, US52490G1022, Illustration mit AI erstellt.

Legend Biotech stock (ISIN US52490G1022) closed at USD 19.11 on Nasdaq on September 25, 2026, while the company entered a new leadership phase after its first profitable quarter. The latest analyst view keeps the valuation debate firmly tied to CARVYKTI execution and pipeline durability.

Analyst target stays at USD 65.00

Investing.com reported on September 28, 2026, that H.C. Wainwright reiterated a Buy rating and a USD 65.00 price target. The target is USD 45.89 above the September 25 price, a difference of 240.15 percent.

The broader analyst picture is less uniform. MarketBeat reported on September 26, 2026, that 15 analysts held a consensus Hold rating and an average 12-month target of USD 53.14, with eight Buy, six Hold and one Sell rating.

Q2 revenue rose 51.9 percent

Legend Biotech generated USD 387.50 million in Q2 2026 revenue, compared with USD 355.96 million expected by analysts, according to MarketBeat. Revenue increased 51.9 percent from the same quarter a year earlier, while quarterly EPS reached USD 0.09 against a USD 0.07 consensus estimate.

The operating milestone matters because the quarter marked company-wide profitability on both IFRS and adjusted bases, while the latest earnings-call material said adjusted net income reached USD 63.00 million. CARVYKTI remains the commercial engine, but Legend is still scaling manufacturing and clinical programs, leaving execution and cash discipline as important counterweights to the bullish target case.

Leadership changes before the next report

Legend Biotech announced on September 15, 2026, that Ingrid Zhang became chief executive officer, succeeding interim CEO Alan Bash. The next earnings report is listed for November 17, 2026, by Investing.com.

LEGN remains below its yearly high

LEGN closed at USD 19.11 on Nasdaq on September 25, 2026. Its 52-week range was USD 16.24 to USD 37.50, placing the share price USD 18.39 below the yearly high and leaving the stock closer to its low than its high.